Novartis Ag

Philip Lake

Prasad Koteswara Kapa

Mahavir Prashad

Hermann Gram

Sushil Kumar Sharma

Mary Ellen Digan

Andrew Kucerovy

Paul G Mattner

Russell C Petter

Gleb Kardash

Fusion polypeptides and salts thereof comprising at least one IgE-binding domain fused to at least one human serum albumin component, optionally via a peptide linker, and in particular, dimeric fusion polypeptides comprising HSA protein fused, at each of its amino and carboxy termini, to an extracellular domain of the &agr;-chain of the human high affinity receptor for IgE (Fc&egr;RI&agr;); process for the preparation thereof, functionally equivalent polypeptides which are intermediates in their preparation, and polynucleotide and oligonucleotide intermediates and vectors therefor. They are indicated for use in the prevention and/or treatment of IgE-mediated allergic diseases and related disorders such as atopic dermatitis, atopic asthma and chronic urticaria.

Fusion polypeptides

An improved process for producing a water-soluble polymyxin B/dextran conjugate comprises the step of reacting polymyxin B or pharmaceutically acceptable salt thereof with dextran in an aqueous media at a pH of about 9.3 to 10.

Improved process for preparing polymyxin B/dextran conjugates

Growing community of inventors

Morris Plains, NJ, United States of America

Philip Lake